From crisis to opportunity: a perspective on the heparin crisis.
Sasisekharan
Ram
R
Massachusetts Institute of Technology, Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA. rams@mit.edu
Shriver
Zachary
Z
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000458:organization & administration*; D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects* / Q000032:analysis / Q000737:chemistry / Q000592:standards; D001208:Asia; D002487:Centers for Disease Control and Prevention, U.S.; D002623:Chemistry Techniques, Analytical; D002648:Child; D002809:Chondroitin Sulfates / Q000009:adverse effects / Q000032:analysis / Q000737:chemistry / Q000494:pharmacology; D003167:Complement Activation / Q000187:drug effects; D004196:Disease Outbreaks / Q000662:veterinary; D004340:Drug Contamination; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology*; D006493:Heparin / Q000009:adverse effects* / Q000032:analysis / Q000737:chemistry / Q000592:standards; D006801:Humans; D007610:Kallikreins / Q000378:metabolism; D015394:Molecular Structure; D019318:Porcine Reproductive and Respiratory Syndrome / Q000453:epidemiology; D013552:Swine; D014481:United States; D014486:United States Food and Drug Administration
D000925:Anticoagulants; D006493:Heparin; D002809:Chondroitin Sulfates; D007610:Kallikreins